CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 150 enrolled
Drug / intervention
esmololdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06390748
NCT06390748Phase 2Completed
CompareCT.gov

Investigating the Immunomodulatory Effects of Esmolol in Sepsis Management and Its Impact on Patient Outcomes

Lin Chen·interventional·Posted Apr 30, 2024·Updated May 29, 2024

In Brief

A Phase 2 clinical trial evaluating esmolol for Sepsis and 6 related conditions. Completed, enrolled 150 participants across 1 site.

Detailed Summary

Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSepsis, Lymphocyte Disorder T, Immunologic Paralysis, Catecholamine; Overproduction, Beta-Blocker, Cytokine Storm, Sympathetic Nervous System Diseases
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 30, 2024
Enrollment StartJan 1, 2021
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 2.2 years ago

Interventions

esmololdrug

The primary intervention is the administration of Esmolol. Esmolol was specifically used to evaluate its immunomodulatory effects in patients with sepsis in the study. The dosage was tailored to achieve optimal heart rate control, an integral part of the therapeutic strategy aiming to mitigate the hyperadrenergic state often seen in sepsis. Alongside Esmolol, daily electrocardiogram (ECG) monitoring was incorporated to observe any changes in the QT interval, ensuring cardiac safety due to the known potential cardiac effects of beta-blockers.